Company Overview and News

2
7 Marijuana Stocks to Buy That Won’t Burn You

2017-11-10 investorplace
Marijuana stocks have become a big deal in both the U.S. and Canada as investors, producers and all the others stakeholders involved try to capture their little piece of what’s sure to become a massive industry.
Upvote Downvote

 
An unpopular real estate ETF is remaking itself as a cannabis fund - MarketWatch

2017-11-09 marketwatch
An exchange-traded fund has seen strong performance but little adoption this year is giving itself a makeover, and is turning to cannabis to do it.
Upvote Downvote

 
ETF Shakeup: PureFunds Brand Name Ousted | ETF.com

2017-08-01 etf
After the close of business on Friday, ETF Managers Group (ETFMG) made a rather stunning move when it announced in a press release that the family of PureFunds ETFs would be rebranded with the ETFMG name as of Aug. 1. The move was also documented in a filing to that effect that hit the SEC Edgar database the same day.
Upvote Downvote

 
ETF Shakeup: PureFunds Brand Name Ousted | ETF.com

2017-07-31 etf
After the close of business on Friday, in a rather sudden and stunning press release, ETF Managers Group announced a rebranding of the PureFunds ETFs, the same day a filing to that effect hit the SEC Edgar database.
Upvote Downvote

 
ETF Managers Group Reduces HACK's Management Fee to 0.60%

2017-06-13 marketwired
SUMMIT, NJ--(Marketwired - June 13, 2017) - Today ETF Managers Group LLC (ETFMG) is announcing a reduction in the management fee for the PureFunds ISE Cyber Security ETF (NYSE ARCA: HACK). The new management fee is 0.60%, from 0.75%, and became effective May 1, 2017.
Upvote Downvote

 
ETF Managers Group Launches New FINRA-Registered Broker Dealer

2017-05-03 marketwired
SUMMIT, NJ--(Marketwired - May 03, 2017) - ETF Managers Group LLC (ETFMG), the leading private label issuer of exchange traded funds (ETFs), today announced that it has launched its own FINRA-registered broker dealer, ETFMG Financial LLC, to provide distribution services to its growing family of ETFs.
Upvote Downvote

 
Etf Managers Trust - QUARTERLY NOTICE OF PORTFOLIO HOLDINGS

2017-02-28 sec.gov
As filed with the Securities and Exchange Commission on February 28, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number:  811-22310   ETF Managers Trust (Exact name of registrant as specified in charter)   30 Maple Street, 2nd Floor Summit, NJ 07901 (Address of principal executive offices) (Zip code)   U.
Upvote Downvote

 
ETF Industry to Get a Product on Marijuana?

2017-02-23 zacks
Any industry that is growing by leaps and bounds does not skip ETF issuers’ eyes. The marijuana industry is on a tear lately. As per the source, cannabis-related stocks added about 236% in 2016. Plus, marijuana sales are likely to boost government’s treasury.
Upvote Downvote

 
ETF Managers Trust AMENDMENT WITHDRAWAL REQUEST

2017-02-17 sec.gov
ETF Managers Trust 30 Maple Street, 2nd Floor Summit, New Jersey 07901 February 17, 2017 VIA EDGAR TRANSMISSION U.S. Securities and Exchange Commission Division of Investment Management 100 F Street, NE Washington, DC 20549 Re: ETF Managers Trust (the “Trust”) File Nos.: 333-182274 and 811-22310 QuantumShares Ultra-Short Treasury/Government ETF (S000054389) QuantumShares Limited-Duration U.S. Government/Corporate ETF (S000054761) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Ac
Upvote Downvote

 
ETF Managers Trust 485APOS

2017-02-16 sec.gov
    As filed with the U.S. Securities and Exchange Commission on February 16, 2017   File No.  333-182274 File No.:  811-22310     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-1A   REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 x Pre-Effective Amendment No.             ¨ Post-Effective Amendment No.    56   x and/or  REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 x Amendment No.
Upvote Downvote

 
ETF Managers Trust XBRL TAXONOMY EXTENSION SCHEMA

2017-02-13 sec.gov
000001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 020000 - Document - Risk/Return Summary {Unlabeled} - PureFunds® ISE Big Data™ ETF link:presentationLink link:definitionLink link:calculationLink 020001 - Schedule - Annual Fund Operating Expenses link:presentationLink link:definitionLink link:calculationLink 020002 - Schedule - Expense Example {Transposed} link:presentationLink link:definitionLink link:calculationLink 020003 - Sche
Upvote Downvote

 
ETF Managers Trust DEFINITIVE MATERIALS FOR XBRL

2017-02-13 sec.gov
Filed Pursuant to Rule 497(c) 1933 Act Registration File No. 333-182274 1940 Act File No. 811-22310 EXPLANATORY NOTE On behalf of ETF Managers Trust and pursuant to Rule 497(c) under the Securities Act of 1933, as amended, attached for filing are XBRL exhibits containing interactive data format risk/return summary information that mirrors the fees and expenses table risk/return summary information contained in the definitive Prospectus dated January 31, 2017, for  PureFunds® ISE Big Data™ ETF, P
Upvote Downvote

 
ETF Managers Trust XBRL TAXONOMY EXTENSION SCHEMA

2017-02-13 sec.gov
000001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 020000 - Document - Risk/Return Summary {Unlabeled} - PureFunds® ISE Big Data™ ETF link:presentationLink link:definitionLink link:calculationLink 020001 - Schedule - Annual Fund Operating Expenses link:presentationLink link:definitionLink link:calculationLink 020002 - Schedule - Expense Example {Transposed} link:presentationLink link:definitionLink link:calculationLink 020003 - Sche
Upvote Downvote

 
ETF Managers Trust POST EFFECTIVE AMENDMENT - RULE 485B FOR XBRL

2017-02-13 sec.gov
As filed with the U.S. Securities and Exchange Commission on February 13, 2017 File No.  333-182274 File No.:  811-22310 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-1A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ☒ Pre‑Effective Amendment No.             ☐ Post‑Effective Amendment No. 55 ☒ and/or  REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 ☒ Amendment No.
Upvote Downvote

 
ETF Managers Trust XBRL TAXONOMY EXTENSION SCHEMA

2017-02-13 sec.gov
000001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 020000 - Document - Risk/Return Summary {Unlabeled} - BlueStar TA-BIGITech™ Israel Technology ETF link:presentationLink link:definitionLink link:calculationLink 020001 - Schedule - Annual Fund Operating Expenses link:presentationLink link:definitionLink link:calculationLink 020002 - Schedule - Expense Example {Transposed} link:presentationLink link:definitionLink link:calculationLin
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...